{"id":27495,"date":"2022-11-22T13:06:38","date_gmt":"2022-11-22T20:06:38","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/uncategorized\/ivig-for-cidp-2\/"},"modified":"2026-03-24T09:56:51","modified_gmt":"2026-03-24T16:56:51","slug":"ivig-for-cidp","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/","title":{"rendered":"IgIV para la CIDP: beneficios, efectos secundarios y tasas de \u00e9xito"},"content":{"rendered":"<p>La inmunoglobulina intravenosa (IVIG) es un tratamiento seguro y eficaz aprobado por la FDA para la CIDP. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/living-with-cidp\/\">Polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica<\/a> (CIDP) es un trastorno neurol\u00f3gico cr\u00f3nico a largo plazo que empeora con el tiempo y afecta a alrededor de <a href=\"https:\/\/rarediseases.org\/rare-diseases\/chronic-inflammatory-demyelinating-polyneuropathy\/\" target=\"_blank\" rel=\"noreferrer noopener\">De 5 a 7 de cada 100.000 personas<\/a>.<\/p>\n\n\n\n<div  id=\"call-to-action-370ef1e0c51f97b7f597d162d9f42efb\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga su dosis de IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tInfusi\u00f3n en casa\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p>En la CIDP, las c\u00e9lulas inmunes anormales atacan a las c\u00e9lulas sanas, espec\u00edficamente a las <a href=\"https:\/\/medlineplus.gov\/ency\/article\/002261.htm#:~:text=Myelin%20is%20an%20insulating%20layer,damaged%2C%20these%20impulses%20slow%20down.\" target=\"_blank\" rel=\"noreferrer noopener\">vaina de mielina<\/a> de nervios perif\u00e9ricos (neuronas). Este ataque puede provocar discapacidades funcionales, como debilidad muscular, conducci\u00f3n nerviosa lenta y p\u00e9rdida de sensibilidad en los pacientes.<\/p>\n\n\n\n<p>No existe una cura espec\u00edfica para la CIDP. Sin embargo, durante las \u00faltimas dos d\u00e9cadas, los m\u00e9dicos han recetado IgIV para la CIDP como tratamiento de primera l\u00ednea para aliviar sus s\u00edntomas y disminuir las complicaciones.<\/p>\n\n\n\n<p>A continuaci\u00f3n, analizaremos los beneficios del tratamiento con IgIV para la PDIC. Tambi\u00e9n exploraremos su mecanismo de acci\u00f3n y revisaremos los estudios que eval\u00faan su eficacia para ayudarle a comprender mejor los beneficios de la IgIV en el manejo de su afecci\u00f3n.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#IVIG_Mode_of_Action\" >Modo de acci\u00f3n de la IgIV<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Neutralization_of_Pathogenic_Autoantibodies\" >Neutralizaci\u00f3n de autoanticuerpos pat\u00f3genos<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Modulation_of_the_Immune_System\" >Modulaci\u00f3n del sistema inmunol\u00f3gico<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Suppressing_Inflammation\" >Suprimir la inflamaci\u00f3n<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Fc_Receptor_Blockade\" >Bloqueo del receptor Fc<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Anti-complement_Activity\" >Actividad anticomplemento<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Upregulation_of_Inhibitory_Receptors\" >Regulaci\u00f3n positiva de los receptores inhibitorios<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Standard_IVIG_Dose_for_CIDP_Patients\" >Dosis est\u00e1ndar de IVIG para pacientes con PDIC<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#IVIG_Dose_Adjustments\" >Ajustes de dosis de IgIV<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#IVIG_Treatment_Protocols_and_Administration_for_CIDP\" >Protocolos y administraci\u00f3n de tratamiento con IgIV para la PDIC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#IVIG_Success_Rate_in_CIDP\" >Tasa de \u00e9xito de la IgIV en la PDIC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Research_Findings_on_IVIG_Treatment_for_CIDP\" >Resultados de la investigaci\u00f3n sobre el tratamiento con IgIV para la PDIC<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Significant_Improvements_in_Functional_Disability\" >Mejoras significativas en la discapacidad funcional<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Systematic_Review_Confirms_IVIG_Efficacy\" >Una revisi\u00f3n sistem\u00e1tica confirma la eficacia de la IgIV<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Potential_Side_Effects_of_IVIG_Therapy\" >Posibles efectos secundarios de la terapia con IgIV<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Long-term_Side_Effects_of_IVIG\" >Efectos secundarios a largo plazo de la IgIV<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Managing_the_Side_Effects_of_IVIG\" >Manejo de los efectos secundarios de la IgIV<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Cost_of_IVIG_for_CIDP\" >Costo de la IgIV para la PDIC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#Receive_At-Home_IVIG_Therapy_for_CIDP_from_AmeriPharma%C2%AE_Specialty_Pharmacy\" >Reciba terapia con IgIV en casa para CIDP en la farmacia especializada AmeriPharma\u00ae<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-ivig-mode-of-action\"><span class=\"ez-toc-section\" id=\"IVIG_Mode_of_Action\"><\/span>Modo de acci\u00f3n de la IgIV<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>En la terapia con IgIV para CIDP, los pacientes sanos <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/immunoglobulins-ig\/\">inmunoglobulinas<\/a> Se infunden en las venas del paciente anticuerpos extra\u00eddos del plasma del donante. Estos anticuerpos sanos impiden que las c\u00e9lulas inmunitarias ataquen y destruyan la vaina de mielina de los nervios perif\u00e9ricos.<\/p>\n\n\n\n<p>El mecanismo de acci\u00f3n o los efectos terap\u00e9uticos de la IgIV para la PDIC no se conocen con precisi\u00f3n. Sin embargo, los cient\u00edficos creen que intervienen diferentes mecanismos de acci\u00f3n. A continuaci\u00f3n, se presenta una descripci\u00f3n general de... <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12499466\/\" target=\"_blank\" rel=\"noreferrer noopener\">posibles mecanismos<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-neutralization-of-pathogenic-autoantibodies\"><span class=\"ez-toc-section\" id=\"Neutralization_of_Pathogenic_Autoantibodies\"><\/span>Neutralizaci\u00f3n de autoanticuerpos pat\u00f3genos<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Las soluciones de IgIV contienen anticuerpos que pueden unirse y neutralizar los autoanticuerpos que atacan la vaina de mielina, la capa protectora del nervio. Esto <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-mechanism-of-action-unraveling-the-enigma-of-this-potent-therapy\/\">mecanismo de acci\u00f3n<\/a> Reduce la presencia de autoanticuerpos da\u00f1inos, minimizando el da\u00f1o inmunomediado infligido a los nervios perif\u00e9ricos.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-modulation-of-the-immune-system\"><span class=\"ez-toc-section\" id=\"Modulation_of_the_Immune_System\"><\/span>Modulaci\u00f3n del sistema inmunol\u00f3gico<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Los pacientes con CIDP que reciben tratamiento con IgIV pueden experimentar una actividad inmunitaria modulada. La IgIV regula la activaci\u00f3n y la funci\u00f3n de c\u00e9lulas inmunitarias como los linfocitos B y T, fundamentales para el sistema de defensa del organismo.<\/p>\n\n\n\n<p>Al regular estas c\u00e9lulas, la IgIV reduce la producci\u00f3n de autoanticuerpos y restablece el equilibrio de un sistema inmunol\u00f3gico hiperactivo.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-suppressing-inflammation\"><span class=\"ez-toc-section\" id=\"Suppressing_Inflammation\"><\/span>Suprimir la inflamaci\u00f3n<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Las propiedades antiinflamatorias de la IgIV para la PDIC pueden estar mediadas por su interacci\u00f3n con sustancias proinflamatorias. Mediadores inflamatorios como las citocinas y las quimiocinas intervienen en el proceso inflamatorio. Al atenuar sus se\u00f1ales, la IgIV puede ayudar a suprimir la inflamaci\u00f3n.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-fc-receptor-blockade\"><span class=\"ez-toc-section\" id=\"Fc_Receptor_Blockade\"><\/span>Bloqueo del receptor Fc<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>La IgIV puede bloquear los receptores Fc de las c\u00e9lulas inmunes que participan en la inflamaci\u00f3n y pueden contribuir al da\u00f1o nervioso.<\/p>\n\n\n\n<p>Este bloqueo ayuda a reducir la actividad de estas c\u00e9lulas inmunes, mitigando a\u00fan m\u00e1s la respuesta inflamatoria y protegiendo la vaina de mielina de lesiones adicionales.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-anti-complement-activity\"><span class=\"ez-toc-section\" id=\"Anti-complement_Activity\"><\/span>Actividad anticomplemento<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Otro mecanismo propuesto para la IgIV en la enfermedad de PDIC es su interferencia con el sistema del complemento. Este sistema forma parte de la respuesta inmunitaria que puede exacerbar la inflamaci\u00f3n y el da\u00f1o nervioso.<\/p>\n\n\n\n<p>La capacidad del tratamiento con IgIV para interrumpir la activaci\u00f3n da\u00f1ina del complemento en la enfermedad CIDP podr\u00eda reducir la lesi\u00f3n tisular y mejorar la protecci\u00f3n nerviosa.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-upregulation-of-inhibitory-receptors\"><span class=\"ez-toc-section\" id=\"Upregulation_of_Inhibitory_Receptors\"><\/span>Regulaci\u00f3n positiva de los receptores inhibitorios<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El uso de IgIV para la enfermedad de PDIC tambi\u00e9n puede provocar un aumento de receptores inhibidores espec\u00edficos, como el Fc\u03b3RIIb. Estos receptores ayudan a inhibir la activaci\u00f3n excesiva de las c\u00e9lulas inmunitarias, disminuyendo as\u00ed la inflamaci\u00f3n y promoviendo una respuesta inmunitaria m\u00e1s equilibrada.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-standard-ivig-dose-for-cidp-patients\"><span class=\"ez-toc-section\" id=\"Standard_IVIG_Dose_for_CIDP_Patients\"><\/span>Dosis est\u00e1ndar de IVIG para pacientes con PDIC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Seg\u00fan varios estudios cl\u00ednicos, la dosis est\u00e1ndar de IgIV para el tratamiento de la CIDP es de 2 g\/kg o (20 ml\/kg) con una duraci\u00f3n de infusi\u00f3n de 3 a 5 horas.<\/p>\n\n\n\n<p>Esta dosis de carga inicial se administra por v\u00eda intravenosa durante 2 a 5 d\u00edas, seguida de una dosis de mantenimiento de 1 g\/kg o (10 ml\/kg) durante 1 d\u00eda cada 3 a 4 semanas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ivig-dose-adjustments\"><span class=\"ez-toc-section\" id=\"IVIG_Dose_Adjustments\"><\/span>Ajustes de dosis de IgIV<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>En algunos casos, la dosis est\u00e1ndar de IgIV para la PDIC puede resultar ineficaz en algunos pacientes. Por lo tanto, se suelen considerar dosis m\u00e1s altas o infusiones m\u00e1s frecuentes de IgIV para lograr la eficacia.<\/p>\n\n\n\n<p>Por ejemplo, en un estudio de caso de una CIDP grave y persistente, los pacientes que no responden bien a la dosis est\u00e1ndar pueden ser tratados con una dosis m\u00e1s alta. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6465009\/\" target=\"_blank\" rel=\"noreferrer noopener\">Dosis de IgIV de 3 g o 30 ml\/kg\/mes durante cinco d\u00edas consecutivos<\/a>.<\/p>\n\n\n\n<p>Sin embargo, la siguiente dosis podr\u00eda variar dependiendo del estado de salud del paciente, el grado de respuesta al tratamiento con inmunoglobulinas y la mejor\u00eda de los s\u00edntomas de CIDP.<\/p>\n\n\n\n<div  id=\"call-to-action-64c5a505aec1b2ba4b124dacc07f7302\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago de IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tAsistencia financiera para la IgIV\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/#form\">Consulte a un especialista en IgIV<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ivig-treatment-protocols-and-administration-for-cidp\"><span class=\"ez-toc-section\" id=\"IVIG_Treatment_Protocols_and_Administration_for_CIDP\"><\/span>Protocolos y administraci\u00f3n de tratamiento con IgIV para la PDIC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La administraci\u00f3n de IgIV para la PDIC es un proceso sencillo. Generalmente, la administraci\u00f3n de IgIV para la PDIC implica los siguientes pasos:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>El proveedor de atenci\u00f3n m\u00e9dica prepara la soluci\u00f3n de IgIV seg\u00fan la dosis prescrita.<\/li>\n\n\n\n<li>Para la infusi\u00f3n el paciente se sienta o se acuesta c\u00f3modamente.<\/li>\n\n\n\n<li>Se inserta una l\u00ednea intravenosa (IV) en la vena del paciente.<\/li>\n\n\n\n<li>La soluci\u00f3n de IgIV se infunde lentamente durante 3 a 5 horas.<\/li>\n\n\n\n<li>Se controlan los signos vitales durante toda la infusi\u00f3n para detectar cualquier reacci\u00f3n adversa.<\/li>\n\n\n\n<li>La velocidad de infusi\u00f3n se puede ajustar seg\u00fan la tolerancia del paciente.<\/li>\n\n\n\n<li>Una vez finalizado, se retira la v\u00eda intravenosa y se observa al paciente para detectar efectos secundarios inmediatos.<\/li>\n\n\n\n<li>Se programa una cita de seguimiento para evaluar la eficacia de la IgIV para la CIDP y ajustar las dosis futuras si es necesario.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ivig-success-rate-in-cidp\"><span class=\"ez-toc-section\" id=\"IVIG_Success_Rate_in_CIDP\"><\/span>Tasa de \u00e9xito de la IgIV en la PDIC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"280\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/woman-smiling-ivig-success.jpg\" alt=\"A woman smiling by the beach\" class=\"wp-image-27540\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/woman-smiling-ivig-success.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/woman-smiling-ivig-success-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/woman-smiling-ivig-success-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/woman-smiling-ivig-success-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/woman-smiling-ivig-success-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/woman-smiling-ivig-success-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/woman-smiling-ivig-success-370x247.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>El objetivo principal de la IgIV para el tratamiento de la CIDP es reducir sustancialmente los s\u00edntomas del paciente, mejorar la capacidad funcional de su cuerpo, prevenir las reca\u00eddas y mantener la remisi\u00f3n a largo plazo.<\/p>\n\n\n\n<p>A diferencia del est\u00e1ndar <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/how-to-treat-cidp-and-what-to-expect\/\">Tratamientos de CIDP<\/a>, como los corticosteroides y <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-vs-plasmapheresis\/\">plasmaf\u00e9resis<\/a> (plasmaf\u00e9resis), la IgIV presenta una respuesta m\u00e1s r\u00e1pida y una alta tasa de \u00e9xito. La mejor\u00eda de los s\u00edntomas de la PDIC se observa al mes de la infusi\u00f3n de IgIV.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-research-findings-on-ivig-treatment-for-cidp\"><span class=\"ez-toc-section\" id=\"Research_Findings_on_IVIG_Treatment_for_CIDP\"><\/span>Resultados de la investigaci\u00f3n sobre el tratamiento con IgIV para la PDIC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Varios estudios cl\u00ednicos han reportado resultados satisfactorios con IgIV para la PDIC. Analicemos cada uno de estos estudios y sus hallazgos.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-significant-improvements-in-functional-disability\"><span class=\"ez-toc-section\" id=\"Significant_Improvements_in_Functional_Disability\"><\/span>Mejoras significativas en la discapacidad funcional<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A <a href=\"https:\/\/jamanetwork.com\/journals\/jamaneurology\/article-abstract\/800552\" target=\"_blank\" rel=\"noreferrer noopener\">ensayo controlado aleatorio realizado en 117 individuos<\/a> demostr\u00f3 que 54% de los pacientes que recibieron terapia con IgIV para CIDP mostraron una discapacidad funcional mejorada a las 24 semanas en comparaci\u00f3n con la tasa de placebo de 21%.<\/p>\n\n\n\n<p>Este ensayo utiliz\u00f3 la escala de discapacidad ajustada INCAT (Inflammatory Neuropathic Cause and Treatment) para evaluar las mejoras. Se observ\u00f3 una mejora significativa de la fuerza muscular y de agarre en los pacientes tratados con IgIV.<\/p>\n\n\n\n<p>Adem\u00e1s, el 60% de los pacientes mostr\u00f3 una respuesta m\u00e1xima a la IgIV a las 6 semanas. Estos hallazgos indican que la intervenci\u00f3n temprana con IgIV es esencial para que los pacientes con PDIC maximice la mejor\u00eda de los s\u00edntomas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-systematic-review-confirms-ivig-efficacy\"><span class=\"ez-toc-section\" id=\"Systematic_Review_Confirms_IVIG_Efficacy\"><\/span>Una revisi\u00f3n sistem\u00e1tica confirma la eficacia de la IgIV<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>En otro an\u00e1lisis exhaustivo, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10865446\/\" target=\"_blank\" rel=\"noreferrer noopener\">una revisi\u00f3n sistem\u00e1tica<\/a> Un estudio de cinco ensayos cl\u00ednicos realizados en 235 sujetos con CIDP tambi\u00e9n destac\u00f3 los beneficios del tratamiento con IgIV para la CIDP.<\/p>\n\n\n\n<p>Esta revisi\u00f3n encontr\u00f3 que quienes recibieron terapia con IgIV para CIDP experimentaron mejoras consistentes en sus puntajes de discapacidad dentro de las seis semanas posteriores al inicio del tratamiento, en comparaci\u00f3n con aquellos que recibieron placebo.<\/p>\n\n\n\n<p>El an\u00e1lisis subray\u00f3 el potencial de la IgIV como opci\u00f3n de tratamiento de primera l\u00ednea, en particular para casos cr\u00f3nicos, con evidencia que destaca sus beneficios sostenidos incluso 24 semanas despu\u00e9s de la terapia.<\/p>\n\n\n\n<p>Con base en estos hallazgos cl\u00ednicos, la IgIV es un tratamiento eficaz y bien tolerado, con resultados prometedores en el tratamiento de la PDIC. La IgIV tambi\u00e9n puede ser una opci\u00f3n a largo plazo para la PDIC, gracias a su baja tasa de efectos secundarios a largo plazo.<\/p>\n\n\n\n<div  id=\"call-to-action-3cbced49a69c6db50c251c40312834ab\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\t\u00bfPuede ayudar la IgIV?\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tInformaci\u00f3n gratuita sobre el tratamiento con IgIV\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-potential-side-effects-of-ivig-therapy\"><span class=\"ez-toc-section\" id=\"Potential_Side_Effects_of_IVIG_Therapy\"><\/span>Posibles efectos secundarios de la terapia con IgIV<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La terapia con IgIV suele ser segura y eficaz. Sin embargo, puede tener efectos secundarios. Si bien la mayor\u00eda son leves y controlables, es fundamental que quienes se sometan al tratamiento los conozcan.<\/p>\n\n\n\n<p>Aqu\u00ed est\u00e1n los m\u00e1s <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-common-side-effects-of-ivig-treatment\/\">efectos secundarios comunes del tratamiento con IgIV<\/a>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>N\u00e1useas<\/li>\n\n\n\n<li>Fatiga<\/li>\n\n\n\n<li>Enrojecimiento<\/li>\n\n\n\n<li>Dolor de cabeza<\/li>\n\n\n\n<li>dolores musculares<\/li>\n\n\n\n<li>Fiebre o escalofr\u00edos<\/li>\n\n\n\n<li>Dolor abdominal<\/li>\n\n\n\n<li>malestar en el pecho<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-long-term-side-effects-of-ivig\"><span class=\"ez-toc-section\" id=\"Long-term_Side_Effects_of_IVIG\"><\/span>Efectos secundarios a largo plazo de la IgIV<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>En raras ocasiones, la terapia con IgIV puede provocar efectos secundarios m\u00e1s graves, especialmente con el uso a largo plazo. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-long-term-side-effects\/\">Efectos secundarios a largo plazo de la IgIV<\/a> Para CIDP puede incluir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Mayor riesgo de co\u00e1gulos sangu\u00edneos (complicaciones tromboemb\u00f3licas)<\/li>\n\n\n\n<li>Lesi\u00f3n renal, especialmente en pacientes mayores o con afecciones preexistentes<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-managing-the-side-effects-of-ivig\"><span class=\"ez-toc-section\" id=\"Managing_the_Side_Effects_of_IVIG\"><\/span>Manejo de los efectos secundarios de la IgIV<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El control de los efectos secundarios del tratamiento con IgIV para la enfermedad de PDIC se puede lograr mediante diversas estrategias. Muchos pacientes descubren que la comunicaci\u00f3n constante con su profesional de la salud y las medidas preventivas pueden mejorar su experiencia.<\/p>\n\n\n\n<p>Algunas estrategias de gesti\u00f3n eficaces incluyen:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hidrataci\u00f3n:<\/strong> Beber muchos l\u00edquidos antes, durante y despu\u00e9s del tratamiento puede ayudar a minimizar los efectos secundarios.<\/li>\n\n\n\n<li><strong>Disminuci\u00f3n de la velocidad de infusi\u00f3n:<\/strong> Ajustar la velocidad de infusi\u00f3n de IgIV para la CIDP puede reducir el riesgo o la gravedad de las complicaciones.<\/li>\n\n\n\n<li><strong>Premedicaci\u00f3n:<\/strong> Tomar medicamentos de venta libre como acetaminof\u00e9n o antihistam\u00ednicos antes de la infusi\u00f3n puede ayudar a aliviar los s\u00edntomas leves.<\/li>\n\n\n\n<li><strong>Monitoreo de s\u00edntomas:<\/strong> El seguimiento de las reacciones durante y despu\u00e9s de la terapia con IgIV puede ayudar a su proveedor de atenci\u00f3n m\u00e9dica a realizar los ajustes necesarios para el tratamiento de la CIDP.<\/li>\n\n\n\n<li><strong>Medidas de comodidad:<\/strong> Descansar y usar almohadillas t\u00e9rmicas o compresas fr\u00edas pueden aliviar las molestias durante y despu\u00e9s de la infusi\u00f3n.<\/li>\n<\/ul>\n\n\n\n<p>Siempre consulte a su equipo de atenci\u00f3n m\u00e9dica para obtener estrategias personalizadas basadas en su situaci\u00f3n particular.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cost-of-ivig-for-cidp\"><span class=\"ez-toc-section\" id=\"Cost_of_IVIG_for_CIDP\"><\/span>Costo de la IgIV para la PDIC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"657\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/ivig-cidp-hospital-1-1024x657-1.jpg\" alt=\"A person receiving IV treatment\" class=\"wp-image-27541\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/ivig-cidp-hospital-1-1024x657-1.jpg 1024w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/ivig-cidp-hospital-1-1024x657-1-300x192.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/ivig-cidp-hospital-1-1024x657-1-768x493.jpg 768w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/ivig-cidp-hospital-1-1024x657-1-600x385.jpg 600w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/ivig-cidp-hospital-1-1024x657-1-86x55.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/ivig-cidp-hospital-1-1024x657-1-167x107.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/ivig-cidp-hospital-1-1024x657-1-280x180.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/ivig-cidp-hospital-1-1024x657-1-370x237.jpg 370w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/11\/ivig-cidp-hospital-1-1024x657-1-960x616.jpg 960w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>El <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/cost-of-ivig-treatment\/\">Costo del tratamiento con IgIV<\/a> El costo de la CIDP puede ser considerable, con frecuencia entre 100 y 350 d\u00f3lares por gramo. En promedio, el costo total del tratamiento puede ascender a aproximadamente 9720 d\u00f3lares anuales.<\/p>\n\n\n\n<p>Diversos factores contribuyen a estos gastos, incluidos los espec\u00edficos <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-brand-reviews\/\">marca de IgIV<\/a> y los requisitos de dosis. Comprender las implicaciones financieras de la terapia con IgIV puede ayudarle a planificar adecuadamente.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-receive-at-home-ivig-therapy-for-cidp-from-ameripharma-specialty-pharmacy\"><span class=\"ez-toc-section\" id=\"Receive_At-Home_IVIG_Therapy_for_CIDP_from_AmeriPharma%C2%AE_Specialty_Pharmacy\"><\/span>Reciba terapia con IgIV en casa para CIDP en la farmacia especializada AmeriPharma\u00ae<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El manejo de la PDIC puede ser dif\u00edcil, pero el tratamiento con IgIV lo hace posible. La IgIV ofrece un enfoque comprobado para aliviar los s\u00edntomas y mejorar la funcionalidad de los pacientes. Con un protocolo de tratamiento bien establecido, los pacientes pueden encontrar alivio y mejorar su calidad de vida.<\/p>\n\n\n\n<p>Si desea recibir infusiones de IgIV en casa para la CIDP, <a href=\"https:\/\/ameripharmaspecialty.com\/es\/about-us\/\">Farmacia especializada AmeriPharma\u00ae<\/a> puede ayudar. Nuestro certificado URAC <a href=\"https:\/\/ameripharmaspecialty.com\/es\/\">farmacia especializada<\/a> proporciona <a href=\"https:\/\/ameripharmaspecialty.com\/es\/home-infusion\/\">servicios de infusi\u00f3n a domicilio<\/a> en m\u00e1s de 40 estados y territorios de EE. UU.<\/p>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/contact-us\/\">Cont\u00e1ctanos<\/a> Hoy para hablar con un especialista y recibir tratamiento con coordinaci\u00f3n de servicios completos, <a href=\"https:\/\/ameripharmaspecialty.com\/es\/financial-assistance\/\">asistencia para copagos<\/a>y soporte 24\/7\/365.<\/p>","protected":false},"excerpt":{"rendered":"<p>La inmunoglobulina intravenosa (IVIG) es un tratamiento seguro, aprobado por la FDA y eficaz para la polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica (PDIC). La PDIC es un trastorno neurol\u00f3gico cr\u00f3nico a largo plazo que empeora con el tiempo y afecta a entre 5 y 7 de cada 100\u00a0000 personas.<\/p>","protected":false},"author":7,"featured_media":27494,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[4],"tags":[8],"class_list":["post-27495","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-other-health-conditions","tag-dr-christine-leduc"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IVIG for CIDP: Benefits, Side Effects, and Success Rates<\/title>\n<meta name=\"description\" content=\"IVIG is a leading treatment for CIDP. Explore how it works, its effectiveness, side effects, and what patients can expect during therapy in this in-depth guide.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIG for CIDP: Benefits, Side Effects, and Success Rates\" \/>\n<meta property=\"og:description\" content=\"IVIG is a leading treatment for CIDP. Explore how it works, its effectiveness, side effects, and what patients can expect during therapy in this in-depth guide.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-22T20:06:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T16:56:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Christine Leduc, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Christine Leduc, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/\"},\"author\":{\"name\":\"Dr. Christine Leduc, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/0d161a7a3c2b0cf54ab0cf25c936dd87\"},\"headline\":\"IVIG for CIDP: Benefits, Side Effects, and Success Rates\",\"datePublished\":\"2022-11-22T20:06:38+00:00\",\"dateModified\":\"2026-03-24T16:56:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/\"},\"wordCount\":1487,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/headache-ivig-for-cidp.jpg\",\"keywords\":[\"Dr. Christine Leduc\"],\"articleSection\":[\"Other Health Conditions\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/\",\"name\":\"IVIG for CIDP: Benefits, Side Effects, and Success Rates\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/headache-ivig-for-cidp.jpg\",\"datePublished\":\"2022-11-22T20:06:38+00:00\",\"dateModified\":\"2026-03-24T16:56:51+00:00\",\"description\":\"IVIG is a leading treatment for CIDP. Explore how it works, its effectiveness, side effects, and what patients can expect during therapy in this in-depth guide.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/headache-ivig-for-cidp.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/headache-ivig-for-cidp.jpg\",\"width\":1280,\"height\":853,\"caption\":\"A woman holding her head in pain\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/other-health-conditions\\\/ivig-for-cidp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIG for CIDP: Benefits, Side Effects, and Success Rates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/0d161a7a3c2b0cf54ab0cf25c936dd87\",\"name\":\"Dr. Christine Leduc, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"caption\":\"Dr. Christine Leduc, PharmD\"},\"description\":\"Dr. Christine Leduc, PharmD, was born and raised in Irvine, CA. She attended college at Midwestern University, where she graduated cum laude. The most rewarding part of her job is suggesting lifestyle changes, educating patients on how their medication works, and precepting future pharmacists. Her areas of expertise are customer service and knowledge of specialty medication. Having worked in the service industry in the past, she has gained the customer service skills necessary to understand the needs of her patients. Dr. Leduc is currently precepting students from Marshall B. Ketchum University, University of Kansas, and Midwestern University. In her free time, she enjoys traveling, baking, and gardening. See Author Biography\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/christine-leduc\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgIV para la CIDP: beneficios, efectos secundarios y tasas de \u00e9xito","description":"La IgIV es un tratamiento l\u00edder para la PDIC. Descubra c\u00f3mo funciona, su eficacia, sus efectos secundarios y qu\u00e9 pueden esperar los pacientes durante el tratamiento en esta gu\u00eda detallada.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/","og_locale":"es_MX","og_type":"article","og_title":"IVIG for CIDP: Benefits, Side Effects, and Success Rates","og_description":"IVIG is a leading treatment for CIDP. Explore how it works, its effectiveness, side effects, and what patients can expect during therapy in this in-depth guide.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2022-11-22T20:06:38+00:00","article_modified_time":"2026-03-24T16:56:51+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg","type":"image\/jpeg"}],"author":"Dr. Christine Leduc, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Christine Leduc, PharmD","Est. reading time":"8 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/"},"author":{"name":"Dr. Christine Leduc, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/0d161a7a3c2b0cf54ab0cf25c936dd87"},"headline":"IVIG for CIDP: Benefits, Side Effects, and Success Rates","datePublished":"2022-11-22T20:06:38+00:00","dateModified":"2026-03-24T16:56:51+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/"},"wordCount":1487,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg","keywords":["Dr. Christine Leduc"],"articleSection":["Other Health Conditions"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/","url":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/","name":"IgIV para la CIDP: beneficios, efectos secundarios y tasas de \u00e9xito","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg","datePublished":"2022-11-22T20:06:38+00:00","dateModified":"2026-03-24T16:56:51+00:00","description":"La IgIV es un tratamiento l\u00edder para la PDIC. Descubra c\u00f3mo funciona, su eficacia, sus efectos secundarios y qu\u00e9 pueden esperar los pacientes durante el tratamiento en esta gu\u00eda detallada.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg","width":1280,"height":853,"caption":"A woman holding her head in pain"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/other-health-conditions\/ivig-for-cidp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"IVIG for CIDP: Benefits, Side Effects, and Success Rates"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/0d161a7a3c2b0cf54ab0cf25c936dd87","name":"Dra. Christine Leduc, PharmD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","caption":"Dr. Christine Leduc, PharmD"},"description":"La Dra. Christine Leduc, doctora en farmacia, naci\u00f3 y creci\u00f3 en Irvine, California. Curs\u00f3 estudios universitarios en la Universidad Midwestern, donde se gradu\u00f3 con honores. Lo m\u00e1s gratificante de su trabajo es sugerir cambios en el estilo de vida, educar a los pacientes sobre el funcionamiento de sus medicamentos y ser tutora de futuros farmac\u00e9uticos. Sus \u00e1reas de especializaci\u00f3n son la atenci\u00f3n al cliente y el conocimiento de medicamentos especializados. Tras haber trabajado en el sector servicios, ha adquirido las habilidades de atenci\u00f3n al cliente necesarias para comprender las necesidades de sus pacientes. Actualmente, la Dra. Leduc imparte clases a estudiantes de la Universidad Marshall B. Ketchum, la Universidad de Kansas y la Universidad Midwestern. En su tiempo libre, disfruta de viajar, la reposter\u00eda y la jardiner\u00eda. Ver biograf\u00eda de la autora.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Christine Leduc, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"},"uagb_comment_info":0,"uagb_excerpt":"Intravenous immunoglobulin (IVIG) is a safe, FDA-approved, and efficacious treatment therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a long-term chronic neurological disorder that worsens over time and affects around 5 to 7 out of 100,000 individuals.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/06\/headache-ivig-for-cidp.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Christine Leduc, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/other-health-conditions\/\" rel=\"category tag\">Other Health Conditions<\/a>","rttpg_excerpt":"Intravenous immunoglobulin (IVIG) is a safe, FDA-approved, and efficacious treatment therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a long-term chronic neurological disorder that worsens over time and affects around 5 to 7 out of 100,000 individuals.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=27495"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27495\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/27494"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=27495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=27495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=27495"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}